175 related articles for article (PubMed ID: 36715834)
21. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
22. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Assessment of BRAF Mutation in Preoperative Thyroid Fine-Needle Aspiration Specimens.
Abi-Raad R; Prasad ML; Zheng J; Hui P; Ustun B; Schofield K; Cai G; Adeniran AJ
Am J Clin Pathol; 2021 Jun; 156(1):100-108. PubMed ID: 33527115
[TBL] [Abstract][Full Text] [Related]
25. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.
Shao H; Yu X; Wang C; Wang Q; Guan H
Endocrine; 2014 Jun; 46(2):285-91. PubMed ID: 24272599
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
27. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
28. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
29. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
[TBL] [Abstract][Full Text] [Related]
31. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
32. An Evaluation of Clinicopathological Factors Effective in the Development of Central and Lateral Lymph Node Metastasis in Papillary Thyroid Cancer.
Aydin Buyruk B; Kebapci N; Yorulmaz G; Buyruk A; Kebapci M
J Natl Med Assoc; 2018 Aug; 110(4):384-390. PubMed ID: 30126565
[TBL] [Abstract][Full Text] [Related]
33. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
34. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
35. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.
Zhang J; Wang P; Dykstra M; Gelebart P; Williams D; Ingham R; Adewuyi EE; Lai R; McMullen T
J Pathol; 2012 Oct; 228(2):241-50. PubMed ID: 22744707
[TBL] [Abstract][Full Text] [Related]
36. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
[TBL] [Abstract][Full Text] [Related]
37. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
39. Construction of prediction models for determining the risk of lateral lymph node metastasis in patients with thyroid papillary carcinoma based on gender stratification.
Wu WX; Qi GF; Feng JW; Ye J; Hong LZ; Wang F; Liu SY; Jiang Y
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2511-2523. PubMed ID: 36622416
[TBL] [Abstract][Full Text] [Related]
40. Notch and TGF-β/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma.
Zhang J; Wang Y; Li D; Jing S
Tumour Biol; 2014 Jan; 35(1):379-85. PubMed ID: 23918305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
